EQ-6

EQ-6 is a preclinical **small molecule** neuroprotective candidate being developed by **AxoProtego Therapeutics** for the **prevention of chemotherapy-induced peripheral neuropathy** in cancer patients. The compound is described as an **ethoxyquin-derived** agent licensed from Johns Hopkins University and is reported to bind **heat shock protein 90**, modulating the HSP90 chaperone machinery to block initiation of axonal neurodegeneration and protect peripheral nerves from chemotherapy-induced damage. Available descriptions indicate oral and intravenous bioavailability, rapid accumulation in peripheral nerves, and preclinical evidence that it does not diminish the anticancer activity of agents such as paclitaxel or cisplatin.

Other names

ethoxyquin derivative